Nautilus is building a proprietary proteomics platform that aims to deliver single-molecule sensitivity more quickly, more completely, and less expensively than existing technologies. The company positions its technology to enable deeper, richer understanding of proteins to accelerate basic science research, improve therapeutic development success rates, and advance personalized and predictive medicine. Nautilus plans to use new capital to accelerate development of its platform and to expand its scientific and engineering staff across multiple disciplines and levels. The platform combines biochemistry and computer science to address limitations that have impeded scientific and pharmaceutical R&D. Nautilus has stated its technology will democratize proteomics by making comprehensive protein quantification more accessible.

Total raised

$76M

Funding rounds

1

Latest round

Series B

Latest activity

May 2020